Moteur de recherche d’entreprises européennes

Financement de l’UE (2 998 500 €) : Cellules souches pluripotentes humaines génétiquement modifiées, plateformes fonctionnalisées de fibroïne de soie et bio-encres : une nouvelle solution pour la … Hor 31/10/2017 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

Cellules souches pluripotentes humaines génétiquement modifiées, plateformes fonctionnalisées de fibroïne de soie et bio-encres : une nouvelle solution pour la production de plaquettes ex-vivo à grande échelle, la transfusion et la recherche de médicaments

"The demand for human platelets (plts) for medical research and clinical applications is massive. The primary goal of SilkFUSION is to engineer groundbreaking 3D nanotechnologies for large-scale production of blood plts for human transfusion from human pluripotent stem cells (hPSCs). Our hypothesis is that plt production ex-vivo can be optimized by providing megakaryocytes (Mks) with the correct physical and biochemical environment. To prove this, we will develop a unique technological platform by engineering non-thrombogenic silk-fibroin biomaterial with proteins, that were proven to promote a 55-fold gain in plt production, to create a three-dimensional ex-vivo bone marrow model that will enhance plt release from Mks derived from hPSCs. Our platform will include (i) novel applications to study pathogenetic mechanisms in patients with inherited platelet production disorders using genetically modified hPSCs; (ii) screening technology for predicting therapeutic efficacy of drugs for thrombocytopenic patients. The development of this technology will exploit an extremely innovative approach using silk-fibroin as a bio-ink for 3D printing a ""live chip"" containing viable Mks for reproducible drug testing. Our long-term vision is to foster the production of plts in-vitro for clinical transfusions in humans at a scale and cost that will address current supply challenges regarding (i) immunologically matched products to alloimmunised patients; (ii) “supercharged” platelets with recombinant FVIIa generating plts specifically suited for patients with acute haemorrhage resulting from trauma, surgery and wounded in conflict zones. The successful development and distribution of the SilkFUSION platforms will also offer researchers and clinicians specialized precision instruments and bio-ink kits for determining the safety and efficacy of drugs, reducing costs of ineffective therapies while promoting affordable functional strategies for the development of novel molecules."


Bico Group AB 344 164 €
Institut Gustave Roussy 688 328 €
Integrated Systems Engineering Srl 319 581 €
Knowledge Innovation Market SL 219 773 €
The Chancellor Masters and Scholars of the University of Cambridge 688 328 €
Universita Degli Studi Di Pavia 738 327 €

https://cordis.europa.eu/project/id/767309

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.